The American Thoracic Society (ATS) 2015 International Conference will take place May 15-20 in Denver Colorado. The ATS is a leading medical association dedicated to advancing lung, critical care and sleep medicine.

During the International Conference in Denver patient organisations, clinicians, scientists and industry from around the world will congregate to discuss the latest findings and latest therapies for lung, critical care and sleep medicine. Researchers, clinicians and experts in the Alpha-1 field will be attending the International Conference to present their latest research and findings.

Kamada Ltd. , a plasma-derived protein therapeutics company will host a panel discussion titled, “New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial,” which will be led by Key Opinion Leaders who specialise in treating patients with alpha-1 antitrypsin deficiency on Tuesday May 19th at the ATS International Conference. The panel discussion will be moderated by Pnina Strauss, Vice President-Clinical Development and Intellectual Property at Kamada, who will initiate the discussion with a presentation of the full data set from the Phase 2/3 clinical study of inhaled AAT for the treatment of AATD, which will include the recently reported analyses of lung function and quality-of-life data as well as of other parameters.

Panel participants include:

· Professor Kenneth R. Chapman, MD, director, Canadian Registry for Alpha-1 Antitrypsin Deficiency Asthma and Airway Centre, Toronto Western Hospital, University of Toronto in Toronto, Canada;
· Professor Gerry McElvaney, MD, professor of medicine at RCSI, Beaumont Hospital, Dublin, Ireland;
· Professor Robert Stockley, MD, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham University, Birmingham, United Kingdom; and
· Jan Stolk, MD, Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands and acting chairman of the Alpha 1 International Registry (AIR).